Ebvaciclib - Pfizer
Alternative Names: PF-06873600; PF-3600Latest Information Update: 13 Feb 2025
At a glance
- Originator Pfizer
- Class Antineoplastics; Piperidines; Pyridones; Pyrimidines; Small molecules; Sulfones
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fallopian tube cancer; HER2 negative breast cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 13 Feb 2025 Discontinued - Phase-I/II for HER2-negative-breast-cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Bulgaria, Canada, Japan, Russia, Ukraine (PO)
- 13 Feb 2025 Discontinued - Phase-I/II for HER2-negative-breast-cancer (Metastatic disease, Monotherapy, Second-line therapy or greater) in Bulgaria, Canada, Japan, Russia, Ukraine (PO)
- 30 Oct 2024 Discontinued - Phase-I/II for Fallopian tube cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Bulgaria (PO)